Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals Gross Profit Margin: 94.69%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
REGN Gross Profit Margin Rankings
| Overall | 97th percentile | 92 of 3916 |
| Sector | 95th percentile | 18 of 369 in Healthcare |
| Industry | 88th percentile | 8 of 72 in Biotechnology |
REGN Gross Profit Margin Range, Past 5 Years
| Minimum | 94.69% | Mar 2012 |
| Maximum | 99.66% | Mar 2011 |
| Average | 99.06% |
About Gross Profit Margin
Gross profit margin is the difference between sales and the cost of goods sold divided by revenue. It expresses the relationship between gross profit (sales - cost of goods sold) and sales revenue. More specifically, gross profit margin represents the percentage of each dollar of a company's revenue that is available to cover fixed costs after paying for the goods or services that were sold.
If a company produces widgets and earns $32 million in sales but pays $24 million for the items sold, then the company's gross profit margin would be ($32m - $24m)/$32m = %25.
Learn More
You may also be interested in these REGN related companies
REGN News
$REGN finally crakkin a lil, stood stiff longer then most today
about 9 hours ago by HighGrowthFinancial
about 9 hours ago by HighGrowthFinancial
$REGN a few years ago was worth looking at...i implore you to watch $THLD!!!
about 22 hours ago by SirPerfluous
about 22 hours ago by SirPerfluous
Sanofi (SNY), Regeneron (REGN) Report Additional Positive Data from Study 1003 in Patients w/ heFH
May 29, 6:52AM Street Insider
May 29, 6:52AM Street Insider
Throwing my selective disclosure op-ed out there 1 final time. Have a great weekend. See you Tues. http://stks.co/3zje $FB $JPM $REGN $DNDN
about 6 days ago by bradloncar
about 6 days ago by bradloncar
$REGN Insider Sale: $2.5M of stock sold by Eric Shooter between May 18, 2012 - May 21, 2012 http://stks.co/3vHK
about 10 days ago by MarketBrief
about 10 days ago by MarketBrief
@HighGrowthFinancial et tu $REGN ? Now we're really talking the last dominoes to fall, as we all move into walmart ;o)
about 13 days ago by ronin245
about 13 days ago by ronin245
Finding buyers near its rising 20dma. A biotech that has already doubled ytd $REGN http://chart.ly/f5kwout
about 21 days ago by ivanhoff
about 21 days ago by ivanhoff
Regeneron Announces Presentation at the Bank of America Merrill Lynch 2012 Healthcare Conference
May 10, 9:30AM PR Newswire
May 10, 9:30AM PR Newswire
watching the channel shrink on $REGN .Tomarrow I think we test $125.00
about 22 days ago by HighGrowthFinancial
about 22 days ago by HighGrowthFinancial
Jefferies Trims Target on Regeneron Pharma (REGN) After Arcalyst News, Keeps Buy Rating
May 09, 11:59AM Street Insider
May 09, 11:59AM Street Insider
$PRAA broke resistance. now long $PRAA. Short $SODA. short $REGN.
about 22 days ago by Bobbin4apples
about 22 days ago by Bobbin4apples
Regeneron Announces Participation in J. P. Morgan Biotech: CEO/CFO Conference Call Series
May 09, 9:30AM PR Newswire
May 09, 9:30AM PR Newswire
Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
May 08, 5:04PM PR Newswire
May 08, 5:04PM PR Newswire
FDA panel won't back Regeneron's $REGN Arcalyst for the treatment of gout; vote was unanimous at 11-0
about 23 days ago by Street_Insider
about 23 days ago by Street_Insider
FDA panel won't back Regeneron's (REGN) Arcalyst for the treatment of gout
May 08, 3:26PM Street Insider
May 08, 3:26PM Street Insider
Regeneron (REGN) Shares Swing as FDA Panel Votes Against Safety of Arcalyst
May 08, 3:23PM Street Insider
May 08, 3:23PM Street Insider
FDA panel votes 8-3 Regeneron's $REGN Arcalyst unsafe in gout flares
about 23 days ago by Street_Insider
about 23 days ago by Street_Insider
FDA panel votes 6-5 Regeneron's $REGN Arcalyst works for Gout flares
about 23 days ago by Street_Insider
about 23 days ago by Street_Insider
Regeneron (REGN), Bayer Report Co-Promotion Agreement for EYLEA in Japan
May 08, 8:35AM Street Insider
May 08, 8:35AM Street Insider
Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
May 08, 2:00AM PR Newswire
May 08, 2:00AM PR Newswire
@mitrado I had options on $REGN & sold w nice profit & then watched it go up 40pts. more ..really painful
about 24 days ago by teddowns
about 24 days ago by teddowns
@ThanhVII PT for $VRTX was around 44$ Now? Who knows? Sold at 54$ --- Not being greedy here, even though I feel it can be the next $REGN :-P
about 24 days ago by mitrado
about 24 days ago by mitrado
Very strong stock. Had a very nice run and now in bull flag. $REGN http://chart.ly/nupx2qp
about 26 days ago by CubanMark
about 26 days ago by CubanMark
$REGN Insider Sale: $4.3M of stock sold by Murray Goldberg between May 2, 2012 - May 3, 2012 http://stks.co/3fuY
about 27 days ago by MarketBrief
about 27 days ago by MarketBrief
Baird Maintains an 'Outperform' on Regeneron Pharma (REGN); Still Taking Share AND Growing the Branded Market
Apr 25, 11:05AM Street Insider
Apr 25, 11:05AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| REGN | 135.89 | +0.14 | +0.10% | 12.75B |
| REG | 43.82 | +0.48 | +1.11% | 3.897B |
| REFR | 3.30 | -0.02 | -0.60% | 62.78M |
| RE | 102.14 | +0.92 | +0.91% | 5.440B |
| RDY | 29.43 | -0.39 | -1.31% | 5.054B |
| RDWR | 38.36 | +0.12 | +0.31% | 803.42M |
| RDSA | 62.19 | +0.39 | +0.63% | 192.20B |
| RDS.B | 64.32 | +0.48 | +0.75% | 199.81B |
| RDNT | 2.40 | +0.03 | +1.27% | 88.71M |
| RDN | 2.48 | +0.00 | +0.00% | 330.56M |